Xeris Biopharma Holdings, Inc.
NASDAQ:XERSBiotechnology
+$0.04 today
- Market cap
- $3.10B
- Beta
- 0.90
- P/E (TTM)
- 98.7
- EPS (TTM)
- $0.07
Volume 2.76M
Average 1.66M
XERS Weighted Avg Shares
Average number of basic shares outstanding during the period, used to calculate basic EPS.
Xeris Biopharma Holdings, Inc.NASDAQ: XERS
Weighted Avg Shares · Q1 FY2026 · quarter ended Mar 2026
Weighted avg shares grows in line with its trailing trend
Q1 FY2026 weighted avg shares of 170.52M shares rose 11.9% year over year, in line with the +11.9% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 2.7% from the prior quarter. Over 3 fiscal years it compounded at +5.8% a year.
Context
- Weighted avg shares increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +11.9% toward the trailing-twelve-month pace of +11.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Weighted Avg Shares history
Shares · from the income statement
- Latest · FY2025
- 160.43M USD
- Year-over-year change
- +9.3%
- 4-year CAGR
- +19.4%
| Period | Period end | Weighted Avg Shares | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 160.43M | +9.3% |
| FY2024 | 2024-12-31 | 146.77M | +6.6% |
| FY2023 | 2023-12-31 | 137.67M | +1.5% |
| FY2022 | 2022-12-31 | 135.63M | +71.6% |
| FY2021 | 2021-12-31 | 79.03M | — |
Weighted Avg Shares vs competitors
How XERS compares with its peers on the latest reported figures
- XERS's LTM Mar 2026 weighted avg shares of 167.52M shares is the 2nd highest of the 9 companies compared; the peer median is 53.64M shares.
- Its year-over-year change of +11.9% is the 4th highest of 9, against a peer median of +9.1%.
- Over three fiscal years its annual growth of +5.8% compares with a peer median of +4.6%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | 306.42M | +8.4% | +5.9% | |
| LTM Mar 2026 | 167.52M | +11.9% | +5.8% | |
| LTM Jun 2026 | 104.26M | +0.4% | -0.9% | |
| LTM Sep 2026 | 63.29M | +4.9% | +2.6% | |
| LTM Mar 2026 | 62.03M | +15.9% | +5.5% | |
SEPNSepterna, Inc. | LTM Sep 2026 | 45.24M | +9.8% | — |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | 44.83M | +33.4% | +4.6% |
| LTM Mar 2026 | 26.99M | +3.1% | +2.3% | |
| LTM Mar 2026 | 827.01K | +51.8% | +7.8% | |
| Peer median (excluding XERS) | 53.64M | +9.1% | +4.6% | |
Competitors are the stored peer set for XERS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 49.59M | 110.25M | 163.91M | 203.07M | 291.85M |
| Cost of Revenue | 13.32M | 22.63M | 28.65M | 36.83M | 53.41M |
| Gross Profit | 36.27M | 87.61M | 135.27M | 166.24M | 238.43M |
| Gross Margin | 73.1% | 79.5% | 82.5% | 81.9% | 81.7% |
| Research & Development | 25.16M | 20.97M | 22.34M | 25.56M | 31.17M |
| Selling, General & Admin | 125.72M | 137.75M | 146.1M | 163.48M | 182.37M |
| Operating Expenses | 151.43M | 169.55M | 179.28M | 199.88M | 213.54M |
| Depreciation & Amortization | 1.88M | 12.67M | 13.16M | 12.63M | 12.16M |
| EBITDA | (113.67M) | (69.31M) | (23.74M) | (13.99M) | 12.71M |
| EBITDA Margin | -229.2% | -62.9% | -14.5% | -6.9% | 4.4% |
| Operating Income | (115.16M) | (81.94M) | (44.01M) | (33.65M) | 24.9M |
| Operating Margin | -232.2% | -74.3% | -26.8% | -16.6% | 8.5% |
| Interest Income | 313K | 2.58M | 4.75M | 5.32M | 4.74M |
| Interest Expense | 7.18M | 14.1M | 26.61M | 33.18M | 29.08M |
| Other Income / Expenses | (7.57M) | (14.14M) | (19.49M) | (23.46M) | (24.34M) |
| Income Before Tax | (122.73M) | (96.08M) | (63.5M) | (57.1M) | 554K |
| Pre-Tax Margin | -247.5% | -87.2% | -38.7% | -28.1% | 0.2% |
| Income Tax Expense | 0 | (1.42M) | (1.25M) | (2.27M) | 0 |
| Net Income | (122.73M) | (94.66M) | (62.26M) | (54.84M) | 554K |
| Net Margin | -247.5% | -85.9% | -38.0% | -27.0% | 0.2% |
| EPS (Basic) | (1.55) | (0.70) | (0.45) | (0.37) | 0.00 |
| EPS (Diluted) | (1.55) | (0.70) | (0.45) | (0.37) | 0.00 |
| Weighted Avg Shares | 79.03M | 135.63M | 137.67M | 146.77M | 160.43M |
| Weighted Avg Shares (Diluted) | 79.03M | 135.63M | 137.67M | 146.77M | 172.74M |
Xeris Biopharma Holdings, Inc.
NASDAQ:XERS
Intrinsic Alpha fair value
Locked
Current Price
$16.99
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.